Defensive Dividend Stocks Worth Watching After The AI Sell Off

When fast growing AI and semiconductor stocks come under pressure, some investors look more closely at companies that focus on steady cash flows and regular dividends. The recent sell off sparked by SK Hynix has reminded many that sentiment around high growth themes can change quickly, while interest in dependable dividend payers can hold up differently. This article explores how the current market mood might affect a selection of defensive dividend stocks and what that could mean for income focused portfolios. It will also reveal 3 stocks from the screener that appear positively exposed to this news driven setup.

Ansell (ASX:ANN)

Overview: Ansell is a global supplier of hand and body protection, making surgical and examination gloves, cleanroom gear and industrial protective clothing for healthcare providers, laboratories and workers in sectors such as manufacturing, mining and logistics across more than 100 countries.

Operations: Ansell generates about A$1.1b from Healthcare and A$909.1m from Industrial protection, with revenue spread mainly across North America, Europe, the Middle East and Africa, and the Asia Pacific region.

Market Cap: A$4.5b

Ansell gives you exposure to everyday demand for protective equipment rather than the more volatile swings of high growth tech themes. The company sits in a large and regulated market for personal protective gear, with well known brands and a broad global footprint that support recurring orders from hospitals and industrial clients. The business faces risks, including margin pressure from low cost rivals, exposure to raw material prices and the need to keep integrating acquisitions cleanly. For investors who want a defensive dividend stock tied to workplace safety and healthcare, this mix of strengths and trade offs may warrant a closer look.

Ansell’s steady glove and protective gear demand could be masking a far more interesting balance between resilience and competition. Scan the 3 key rewards and 1 important warning sign to see what might be quietly shifting beneath the surface.

Virtus Health (ASX:VRT)

Overview: Virtus Health is a fertility focused healthcare group that provides IVF and related reproductive services, medical day procedures and diagnostics through a network of fertility specialists and clinics across Australia, Europe and Asia.

Market Cap: A$705.2m

Virtus Health can appeal to dividend focused investors who want healthcare exposure that is less tied to AI or semiconductor cycles and more to ongoing demand for fertility and specialist medical procedures. Earnings grew 83.6% over the past year, with net profit margins at 8.4%, yet the P/E of 24.9x still sits below the broader Healthcare industry and well below peer averages. That said, an unstable dividend history, shareholder dilution and relatively high reliance on external borrowings raise important questions about income reliability and balance sheet risk. Governance is also a watchpoint, given a fully non independent board and limited board tenure. The mix of recent earnings strength, valuation signals and these governance and funding issues makes Virtus Health a stock worth closer examination for income oriented portfolios.

Virtus Health’s 83.6% earnings growth with an 8.4% margin and a P/E of 24.9x hints at a story income investors may be missing. Scan the 2 key rewards and 3 important warning signs (1 is major!) before those governance and funding questions reshape the picture.

Smith & Nephew (LSE:SN.)

Overview: Smith & Nephew is a global medical devices company that supplies joint replacement implants, sports medicine tools, ear, nose and throat products, and advanced wound care therapies used by hospitals and surgeons in procedures such as knee and hip replacements, soft tissue repairs and chronic wound treatment.

Operations: Smith & Nephew generates about $2.4b from Orthopaedics, $1.9b from Sports Medicine & ENT and $1.8b from Advanced Wound Management across the United States, United Kingdom, China, other established markets and emerging markets.

Market Cap: £10.1b

Smith & Nephew may appeal to income-focused investors who want healthcare exposure tied to essential surgeries and wound care rather than AI or chip cycles. The company currently pays a 2.45% dividend and reports revenue growth, margin improvements and a broad product pipeline that includes robotics-assisted surgery platforms and next-generation wound devices. At the same time, debt levels and policy risks around reimbursement and tariffs mean that balance sheet strength and cash generation warrant close attention. With the share price described as trading below some value estimates and supported by a buyback program, the combination of earnings trends, product launches and funding risk presents a more complex picture than a simple defensive label.

Smith & Nephew’s mix of essential surgeries, wound care and robotics assisted platforms could be masking a very different risk reward profile. Scan the 5 key rewards and 1 important warning sign for the twist that income investors rarely factor in.

The three dividend stocks in this article are only a starting point. The full screen uncovers 17 more companies in the Defensive Dividend Stocks screener that also carry compelling income and resilience stories. Use Simply Wall St to identify, filter and analyze the specific catalysts, dividend profiles and financial traits that matter most so you can focus on the highest conviction ideas for your portfolio.

Take Control of Your Investment Journey

If Smith & Nephew or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before Others Do

Some of the most interesting ideas often move first while attention is elsewhere. New themes can build quiet momentum under the radar for now. Do not get caught watching. Consider acting while you have time to evaluate opportunities.

• Explore potential rebounds in niche producers by scanning the 9 top silver producer stocks that could benefit if interest returns to precious metals before the broader market focuses on them.
• Review cash generative tech plays by checking the 66 profitable AI stocks that aren't just burning cash that focus on earnings and balance sheets rather than hype while that difference in emphasis remains notable.
• Assess opportunities linked to infrastructure upgrades with the 34 power grid technology and infrastructure stocks that track companies tied to ageing networks and evolving demand for grid reliability while valuations still reflect earlier assumptions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com